GW Pharmaceuticals seeks FDA nod for spasticity drug trial

08/18/2013 | Pharmaceutical Business Review Online

GW Pharmaceuticals filed an investigational new-drug application with the FDA to conduct a pivotal, late-stage trial of Sativex as a treatment for spasticity in multiple sclerosis patients. The trial, which is expected to begin next year, will be carried out by GW's partner Otsuka Pharmaceutical. The drug is also in late-stage clinical development as a treatment for cancer pain.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD